Purpose T regulatory (Treg) cells, comprising only 5-10% of the peripheral CD4+ T cell population, are known to suppress T cell function in the host immune response. One subtype of Tregs is the Treg-1 (Tr1) cells, which can be generated in Balb/c mice following repeated subcutaneous injection of Toxic Shock Syndrome Toxin-1 (TSST-1), a superantigen secreted by Staphylococcus aureus. The purpose of this study is to assess the modulating effects of TSST-1 induced Tregs on the proliferation and apoptosis of murine B cells in response to TSST-1.
Methods 6-8 week-old female BALB/c mice (n = 6) were administered 4 μg TSST-1 or PBS subcutaneously for 3 doses at 4-day intervals. Mice were sacrificed 2 h after the last injection, and splenocytes were obtained. CD4+CD25+ and CD4+CD25- T cells were purified by magnetic separation. Both groups of CD4+ T cells were co-cultured in a 1:1 ratio with splenic B cells from naïve mice, and restimulated with 1 nM TSST-1 for 3 days in vitro. Co-cultures were treated with anti-CD19-allophycocyanin (APC) to identify the B cell population. Carboxyfluorescein diacetate succinimidyl ester (CFSE) staining was used to track B cell proliferation, and 7-amino actinomycin D (7-AAD) was employed to assess apoptosis.
Results Co-culturing with PBS primed CD4+CD25- T cells in the presence of 1nM TSST-1 caused B cells to undergo at least 3 cycles of proliferation. In contrast, co-culturing with either TSST-1 primed CD4+CD25+ or CD4+CD25- T cells inhibited progression of B cell proliferation (p≤0.05; student t test). 7-AAD staining revealed that TSST-1 primed CD4+CD25+ Tregs in the presence of TSST-1 prevented B cell proliferation by inducing B cell apoptosis. On the other hand, TSST-1 primed CD4+CD25- Tregs did not cause B cell apoptosis, but prevented B cell proliferation likely by down-regulating CD19 expression.
Conclusion These data provides evidence that in addition to modulating T cell activity, TSST-1 induced Tregs also regulate B cell proliferation and apoptosis in response to TSST-1 re-stimulation in vitro. Furthermore, CD4+CD25+ and CD4+CD25- Tregs appear to have different mechanisms of action. These results raises the possibility of using TSST-1 primed CD4+CD25+ or CD4+CD25- Tregs for controlling B cell-mediated autoimmune diseases, such as rheumatoid arthritis or systemic lupus erythematosis.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.